We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Quantum Phar. | LSE:QP. | London | Ordinary Share | GB00BRTL8Q42 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 84.2374 | 84.00 | 84.75 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
TIDMQP.
RNS Number : 9207O
Quantum Pharma PLC
11 November 2016
For immediate release 11 November 2016
This announcement contains inside information
Quantum Pharma Plc
('Quantum' or the 'Company')
Director's Dealings
Quantum Pharma Plc (AIM: QP.) the service-led niche pharmaceutical developer, manufacturer and supplier to the health and care sectors, announces that, following admission earlier today of the 44,117,647 ordinary shares of GBP0.10 each ('Ordinary Shares') in connection with the placing announced on 20 October 2016 (the 'Placing') the following dealings by Directors in the Company's Ordinary Shares, by way of their participation in the Placing, have now taken place at the placing price of 34 pence per Ordinary Share.
Following these dealings, their resulting interests are as follows:
Hot Features
Premium
Director Ordinary Ordinary Ordinary % interest Interest Total
Shares Shares Shares in issued in Ordinary % interest
held purchased held ordinary Shares in issued
prior in the post share via incentive ordinary
to dealing Placing dealing capital arrangements share
(unvested) capital
---------- ------------ ----------- --------- ----------- --------------- ------------
Chris
Rigg 15,000 147,059 162,059 0.10 696,281 0.51
---------- ------------ ----------- --------- ----------- --------------- ------------
Ian
Johnson - 58,824 58,824 0.03 - 0.03
---------- ------------ ----------- --------- ----------- --------------- ------------
Dr.
John
Brown - 73,529 73,529 0.04 - 0.04
---------- ------------ ----------- --------- ----------- --------------- ------------
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ----------------------------------------------------
a) Name Chris Rigg
--- -------------------- ------------------------------
2 Reason for the notification
--- ----------------------------------------------------
a) Position/status CEO and CFO
--- -------------------- ------------------------------
b) Initial Initial notification
notification
/Amendment
--- -------------------- ------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- ----------------------------------------------------
a) Name Quantum Pharma Plc
--- -------------------- ------------------------------
b) LEI (Pending)
--- -------------------- ------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- ----------------------------------------------------
a) Description Ordinary shares of GBP0.10
of the financial
instrument, ISIN: GB00BRTL8Q42
type of
instrument
Identification
code
--- -------------------- ------------------------------
b) Nature of Purchase of Ordinary Shares
the transaction
--- -------------------- ------------------------------
c) Price(s) Price(s) Volume(s)
and volume(s) --------- ----------
34p 147,059
--------- ----------
--- -------------------- ------------------------------
d) Aggregated
information N/A - single transaction
- Aggregated
volume
- Price
--- -------------------- ------------------------------
e) Date of 11 November 2016
the transaction
--- -------------------- ------------------------------
f) Place of London Stock Exchange, AIM
the transaction
--- -------------------- ------------------------------
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ----------------------------------------------------
a) Name Ian Johnson
--- -------------------- ------------------------------
2 Reason for the notification
--- ----------------------------------------------------
a) Position/status Non-Executive Chairman
--- -------------------- ------------------------------
b) Initial Initial notification
notification
/Amendment
--- -------------------- ------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- ----------------------------------------------------
a) Name Quantum Pharma Plc
--- -------------------- ------------------------------
b) LEI (Pending)
--- -------------------- ------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- ----------------------------------------------------
a) Description Ordinary shares of GBP0.10
of the financial
instrument, ISIN: GB00BRTL8Q42
type of
instrument
Identification
code
--- -------------------- ------------------------------
b) Nature of Purchase of Ordinary Shares
the transaction
--- -------------------- ------------------------------
c) Price(s) Price(s) Volume(s)
and volume(s) --------- ----------
34p 58,824
--------- ----------
--- -------------------- ------------------------------
d) Aggregated
information N/A - single transaction
- Aggregated
volume
- Price
--- -------------------- ------------------------------
e) Date of 11 November 2016
the transaction
--- -------------------- ------------------------------
f) Place of London Stock Exchange, AIM
the transaction
--- -------------------- ------------------------------
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ----------------------------------------------------
a) Name Dr John Brown
--- -------------------- ------------------------------
2 Reason for the notification
--- ----------------------------------------------------
a) Position/status Non-Executive Director
--- -------------------- ------------------------------
b) Initial Initial notification
notification
/Amendment
--- -------------------- ------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- ----------------------------------------------------
a) Name Quantum Pharma Plc
--- -------------------- ------------------------------
b) LEI (Pending)
--- -------------------- ------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- ----------------------------------------------------
a) Description Ordinary shares of GBP0.10
of the financial
instrument, ISIN: GB00BRTL8Q42
type of
instrument
Identification
code
--- -------------------- ------------------------------
b) Nature of Purchase of Ordinary Shares
the transaction
--- -------------------- ------------------------------
c) Price(s) Price(s) Volume(s)
and volume(s) --------- ----------
34p 73,529
--------- ----------
--- ----------------- ---------------------------
d) Aggregated
information N/A - single transaction
- Aggregated
volume
- Price
--- ----------------- ---------------------------
e) Date of 11 November 2016
the transaction
--- ----------------- ---------------------------
f) Place of London Stock Exchange, AIM
the transaction
--- ----------------- ---------------------------
- Ends -
For further information:
Quantum Pharma Plc Ian Johnson, Chairman Tel: +44 (0) 1207 Chris Rigg, CEO and CFO 279 404 Craig Swinhoe, Group Strategic www.quantumpharmaplc.com Projects Director and Company Secretary Zeus Capital Limited Tel: +44 (0) 20 (Nominated Adviser & Joint 3829 5000 Broker) Andrew Jones / Nick Cowles www.zeuscapital.co.uk / Jamie Peel Dominic Wilson / Adam Pollock / John Goold N+1 Singer (Joint Broker) Tel: +44 (0) 20 Aubrey Powell / James White 7496 3000 / Sandy Ritchie www.n1singer.com Nick Owen / Brough Ransom Media enquiries: Buchanan Henry Harrison-Topham / Sophie Tel: +44 (0) 20 Cowles / Steph Watson 7466 5000 quantumpharma@buchanan.uk.com www.buchanan.uk.com
Notes to Editors
Quantum Pharma Plc is a service-led, niche pharmaceutical developer, manufacturer and supplier to the retail pharmacy, pharmaceutical wholesaler, hospital, homecare and care home markets. Quantum Pharma operates through three divisions: Specials, Niche Pharmaceuticals and Medication Adherence, offering a portfolio of innovative and complementary products and services.
Specials comprises three business units (Quantum Pharmaceutical, UL Medicines and Quantum Aseptics Services). This division manufactures, procures and supplies bespoke specials; batch made specials; aseptically prepared sterile intravenous medicines; imported medicines and special obtain products in response to a request from a prescriber for a bespoke medicine or special product to optimise patient treatment. The division offers an unrivalled and constantly expanding range of products. It has a customer-focused, service-driven business model, which provides shorter lead times than any of its competitors.
Niche Pharmaceuticals comprises three business units (Colonis, Lamda and PERN Consumer Products). This division is a product development and commercialisation business focusing on taking niche drugs through the regulatory pathway to achieve regulated status (licensed product or medical device). The division uses the excellent visibility of trends in the UK pharmacy and hospital markets gained through our Specials and Medication Adherence divisions, to allow early identification of the market opportunity to take products from unlicensed to licensed status. The division has a growing portfolio and pipeline of products that fit this unlicensed to licensed pathway, as well as complementary generic, generic plus or medical devices intended to meet unmet patient needs across a number of therapeutic areas.
Medication Adherence comprises two business units (Biodose(R) and Biodose Services(R)). This division provides products and services to enhance the likelihood of a patient adhering to a medication regime, patient-focused homecare services and services to pharmaceutical companies. It owns Biodose(R), the only medication delivery system on the market that accommodates both liquid and solid doses. Biodose Connect(TM) takes patient safety and adherence to the next level by enabling remote monitoring of adherence to medication regimes. The division also operates a range of specialist patient-focused homecare services to the NHS, private clinics and pharmaceutical companies and provides the Group with exposure to the homecare and supported living sectors of the care pathway, complementing the focus of the remainder of the Group.
For further information, please visit www.quantumpharmaplc.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHFMMMMNGMGVZM
(END) Dow Jones Newswires
November 11, 2016 03:01 ET (08:01 GMT)
1 Year Quantum Phar. Chart |
1 Month Quantum Phar. Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
